Stocks shook off last Friday’s sell-off with a positive week, but it wasn’t all smooth sailing. Tariff concerns weighed on stocks on Thursday and will continue to be a source of long-term uncertainty.

First-quarter profit halved from a year earlier due in part to the U.S. levies, though the automaker raised its annual earnings forecasts, citing a smaller-than-feared tariff hit. Dine Brands Global ...

The Chart of the Day What we're watching What we're reading Economic data releases and earnings After the Pelotons (PTON) and Zooms (ZM) of the world enjoyed their glorious time in the pandemic sun, ...

Nvidia reiterated that its chips don't-and shouldn't-have back doors or kill switches, days after Beijing summoned the U.S. artificial-intelligence chip giant over national-security concerns. Novo ...

The S&P 500 dropped 0.37% and closed at 6,339.39 for its third straight losing day, while the Nasdaq Composite inched down ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

Hims & Hers (HIMS) telehealth platform drives strong growth, but the Novo Nordisk partnership fallout and regulatory risks pose challenges. Wall Street Bets has fueled meme stock surges in names ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...